Stoke Therapeutics (STOK) Earnings Date
Does this company deliver against its own promises? Earnings are a check on the thesis, not a catalyst to chase.
Estimate-vs-actual scoring began Jul 2026. Earlier quarters predate our snapshots, so their surprise stays "—". We never backfill an estimate we didn't observe.
| Report | Est EPS | Act EPS | Est rev | Act rev | Rev surp. | Reaction |
|---|---|---|---|---|---|---|
| Oct 29, 20268-K, after close · 4:01 pm ET | −0.93 | −1.08 | $8.2M | $11.3M | +37.1% | −0.2%next session |
| Aug 3, 2026 filed | −0.80 | −0.93 | $4.9M | $9.3M | +90.7% | —filing date only |
| May 7, 20268-K, after close · 4:19 pm ET | — | −0.79 | — | $6.2M | — | +0.3%next session |
| Jan 12, 20268-K, before open · 7:34 am ET | — | −0.97 | — | $1.4M | — | −10.4%release day |
| Nov 4, 20258-K, after close · 4:05 pm ET | — | −0.65 | — | $10.6M | — | −9.9%next session |
| Aug 12, 20258-K, after close · 4:01 pm ET | — | −0.40 | — | $13.8M | — | +25.0%next session |
| Mar 18, 20258-K, before open · 7:05 am ET | — | −0.15 | — | $22.6M | — | −1.4%release day |
| Nov 5, 20248-K, before open · 7:05 am ET | — | −0.47 | — | $4.9M | — | −0.4%release day |
filed marks a quarter where we found no results release and hold only the date its report was filed. A filing can trail the release by days or weeks, so those rows show no reaction rather than the move of an unrelated session.
| Measure | Dec '26 | Mar '27 | FY26 | FY27 |
|---|---|---|---|---|
| No. of analysts | 7 | 4 | 9 | 10 |
| Avg estimate | −1.15 | −1.15 | −3.96 | −4.09 |
| Low estimate | −1.35 | −1.22 | −4.14 | −4.75 |
| High estimate | −0.99 | −1.07 | −3.67 | −3.78 |
| Year-ago EPS | −0.97 | −0.79 | −0.12 | −3.96E |
| Implied growth | — | — | — | — |
| Measure | Dec '26 | Mar '27 | FY26 | FY27 |
|---|---|---|---|---|
| No. of analysts | 7 | 5 | 9 | 10 |
| Avg estimate | $8.0M | $6.8M | $35.5M | $47.1M |
| Low estimate | $4.9M | $5.5M | $31.7M | $4.1M |
| High estimate | $13.0M | $8.1M | $43.7M | $102.6M |
| Year-ago revenue | $1.4M | $6.2M | $184.4M | $35.5ME |
| Implied growth | +473.1% | +9.2% | −80.8% | +32.7% |
| Snapshot age | Dec '26, period ending Dec 30, 2026 | Mar '27, period ending Mar 30, 2027 | FY26, period ending Dec 31, 2026 | FY27, period ending Dec 31, 2027 |
|---|---|---|---|---|
| Current estimate | −1.15 | −1.15 | −3.96 | −4.09 |
| 7 days ago | −1.15 | — | −3.96 | −4.09 |
| 30 days ago | −0.98 | — | −3.64 | −3.59 |
| 60 days ago | −0.97 | — | −3.62 | −3.54 |
| 90 days ago | −0.97 | — | −3.62 | −3.52 |
Estimate history accrues from our nightly snapshots. The 7/30/60/90-day rows fill in as tracking continues. Each column follows one fiscal period back through our snapshots; a dash means we had not recorded that period at that age. A rising bar makes a beat streak more meaningful; a falling one manufactures beats.
Dec '26 quarter consensus moved $−0.97 → $−1.15 over 90 tracked days, the same quarter at both ends. Per-analyst up/down revision counts aren't in our data feed. We show the bar's actual movement instead of guessing.
Common questions
What were Stoke Therapeutics' latest quarterly earnings?
Stoke Therapeutics reported diluted EPS of −1.08 and revenue of $11.3M on Oct 29, 2026.
How did Stoke Therapeutics' stock move after its last earnings report?
Stoke Therapeutics moved −0.2% in the session after its Oct 29, 2026 report.

